Replimune posts IGNYTE trial presentation on RP1-nivolumab in anti-PD-1-failed melanoma

Replimune

Replimune

REPL

0.00
  • Replimune published updated IGNYTE trial results for RP1 with nivolumab in anti-PD-1-failed melanoma, reporting 3-year overall survival outcomes.
  • Median overall survival was 32.9 months; 3-year overall survival rate was 47.8%.
  • Objective response rate by RECIST 1.1 was 33.6%, including a 16.4% complete response rate; median duration of response was 24.8 months.
  • Safety profile remained consistent, with no new safety signals; grade 3-4 treatment-related adverse events occurred in 12.8% of patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief on May 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.